Reference is made to the stock exchange announcement from Navamedic ASA (the "Company") published on 13 June 2016 regarding the strategic partnershipand 8-year distribution agreement with TopRidge Pharma Limited and the stock exchange announcement published 17 June 2016 regarding the registration of share capital increase.
The Norwegian Financial Supervisory Authority (Nw. Finanstilsynet) has on 1 November 2016 approved a prospectus prepared by the Company for the listing of 1,417,522 new shares in the Company, each with a nominal value of NOK 1. The new shares, having been registered on a separate ISIN and not been tradable on the Oslo Stock Exchange since its issuance, will following the publication of the prospectus be transferred to the Company's ordinary ISIN and be tradable on the Oslo Stock Exchange. TopRidge has agreed on a lock-up period of 12 months, following the completion date of the investment. In this period the newly issued shares shall not be sold. The prospectus is attached to this stock exchange notice and will also be made available at the Company's website, www.navamedic.com. Printed copies of the prospectus may be obtained free of charge at the offices of the Company in Bærum, Norway.
For further information, please contact Toril Marie Ås, CFO Navamedic ASA, email@example.com, Tel: +47 95 70 10 71.
Navamedic ASA, Bærum, 1 November 2016
This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.Prospectus
Last updated on: 02/11/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.